市場調査レポート

商品コード

1408033

創薬の世界市場の評価：医薬品タイプ別、由来別、技術別、エンドユーザー別、地域別、機会、予測（2017年～2031年）

Global Drug Discovery Market Assessment, By Drug Type, By Source, By Technology, By End-user, By Region, Opportunities and Forecast, 2017-2031F

出版日: 2024年01月15日
発行: Market Xcel - Markets and Data
ページ情報: 英文 218 Pages
納期: 3～5営業日

カスタマイズ可能

価格

PDF & Excel Printable (Single User License)

USD 4,500 660,690円

レポートPDFを1名の方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Corporate License)

USD 5,700 836,874円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能ですが、企業内部での利用に限定されます。ご利用に際しては、あらかじめ出版社の許諾を得る必要があります。詳細はお問合せください。印刷は可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Custom Research License)

USD 8,200 1,203,924円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。アナリストアワー100時間が含まれており、レポートのカスタマイズなどにご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=146.82円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界の創薬の市場規模は、2023年に682億4,000万米ドル、2031年に1,541億2,000万米ドルに達し、2024年～2031年の予測期間にCAGRで10.72%の成長が見込まれています。市場の成長は、さまざまな慢性疾患の流行、医療支出の増加、特定の一般的な医薬品の特許切れ、AIソリューションの採用、官民部門の生物医学研究への投資の増加などのさまざまな要因によって促進されています。

市場は、老年人口の増加によりさらに力強い成長を示しています。出生率の低下、医療施設の増加による平均寿命の伸び、世界中で利用できる老年人口向けの膨大な治療オプションが、人々の長生きを助ける要因となっています。しかし、このことが高齢者の加齢に関連したモダリティや慢性疾患をさらに加速させています。このようなモダリティに対抗するには、創薬における技術革新と研究開発が必要です。さらに、承認された医薬品の安全性と有効性をチェックし、国民の健康を改善するために、あらゆる段階で医薬品の品質と標準を確保し維持する責任を負う規制が各国に存在します。

COVID-19パンデミックは、ケアの動きを加速させ、その結果、さまざまな国で医療支出が増加しました。医療費の増加は、研究、医薬品開発、製造プロセスへの支出の増加により、世界の創薬市場で急増しています。創薬は高価で複雑かつ繊細なプロセスであり、医薬品の研究開発に関連するコストとリスクのため、政府や製薬企業からの資金提供を必要とします。医療支出は、よりよい健康機会の提供につながり、その国の医療システムをさらに強化するとともに世界の創薬市場の成長につながります。

慢性疾患の流行

慢性疾患の流行は、市場の大きな促進要因です。WHOによると、心血管疾患、がん、糖尿病、呼吸器疾患を含む慢性疾患は、世界レベルで毎年4,100万人の死亡の原因となっています。地域や国に関係なく、あらゆる年齢層の人々が罹患しています。不健康な食事、座りがちなライフスタイル、タバコの使用、アルコールの乱用は、発展途上国だけでなく先進国においても慢性疾患を助長する主な危険因子です。有病率の増加は、新薬発見の需要をさらに押し上げています。より健康な未来という目標を達成するため、製薬企業は新薬の発見に向け研究開発を加速させています。新薬の発見には、新しい疾患や慢性疾患、治療不可能な疾患の症状を治療し、薬剤耐性の問題を解決することが必要です。平均寿命が延びるにつれて、人々はこれらの疾患にかかりやすくなり、その結果、世界の創薬市場が成長しています。

創薬への投資の増加

低分子医薬品、タンパク質ベースの生物学的製剤、ワクチン、in vivo診断などのいずれにしても、医薬品の製造をサポートするには多額の官民投資が必要です。こうした組織による投資は、世界の医療目標を達成に向け世界の創薬市場を活性化させています。慢性疾患や新たな疾病の増加に伴い、増加する人口の健康問題に対処するための新薬の開発および創薬が求められています。この需要に応えるため、米国、欧州、アジア太平洋の多くのバイオテクノロジー企業が創薬に多額の投資を行っています。

政府の取り組み

創薬は時間とコストのかかるプロセスであり、そのさまざまな製造ステップにおいて政府からの資金と支援が必要です。政府は創薬の研究開発に数十億米ドルを投じています。この支出は、新薬の創薬や試験、技術革新の開発、安全性モニタリングを目的とした臨床試験など、さまざまな活動に及んでいます。政府は市場を支援するため、多くの取り組み、政策、プログラムを打ち出しています。

高まる生物学的製剤の需要

世界の創薬市場において、生物学的製剤の需要が顕著に急増しています。生物学的製剤というカテゴリは、治療不可能あるいは治療困難と考えられている疾患を治療する大きな可能性を持っているため、勢いを増しています。生物学的製剤には、標的とする疾患の治療により特異的に作用し、その他の薬剤と反応しにくいという特性があります。したがって、複数の薬剤を服用している患者の安全性を確保することができます。こうした特性により生物学的製剤の需要が急増し、日本、英国、インド、中国、米国、スウェーデンなど多くの国が、この需要の増加に対応するため、複雑な生物学的製剤の製造施設の開発に乗り出しています。

当レポートでは、世界の創薬市場について調査分析し、市場規模と予測、市場力学、主要企業の情勢と見通しなどを提供しています。

市場規模と予測
- 金額
- 数量
医薬品タイプ別
- 低分子
- 生物学的製剤
由来別
- 天然
- 合成
技術別
- コンビナトリアルケミストリー
- ハイスループットスクリーニング
- ナノテクノロジー
- 薬理ゲノミクス
- その他の技術
エンドユーザー別
- 製薬企業
- 受託研究機関
- その他
地域別
- 北米
- 欧州
- 南米
- アジア太平洋
- 中東・アフリカ
市場シェア：企業別（2023年）

第6章世界の創薬市場の見通し：地域別（2017年～2031年）

北米
- 市場規模と予測
- 医薬品タイプ別
- 由来別
- 技術別
- エンドユーザー別
- 米国
- カナダ
- メキシコ
欧州
- ドイツ
- フランス
- イタリア
- 英国
- ロシア
- オランダ
- スペイン
- トルコ
- ポーランド
南米
- ブラジル
- アルゼンチン
アジア太平洋
- インド
- 中国
- 日本
- オーストラリア
- ベトナム
- 韓国
- インドネシア
- フィリピン
中東・アフリカ
- サウジアラビア
- アラブ首長国連邦
- 南アフリカ

第7章市場マッピング（2023年）

医薬品タイプ別
由来別
技術別
エンドユーザー別
地域別

第8章マクロ環境と産業構造

需給分析
輸出入の分析
バリューチェーン分析
PESTEL分析
ポーターのファイブフォース分析

第9章市場力学

成長促進要因
成長抑制要因（課題、抑制要因）

第10章規制枠組みとイノベーション

臨床試験
特許情勢
規制当局の承認
イノベーション/新技術

第11章主要企業情勢

マーケットリーダー上位5社の競合マトリクス
マーケットリーダー上位5社の市場収益分析（2023年）
合併と買収/合弁事業（該当する場合）
SWOT分析（市場参入企業5社）
特許分析（該当する場合）

第12章価格分析

第13章ケーススタディ

第14章主要企業の見通し

Johnson & Johnson Inc.
F. Hoffmann-La Roche Ltd.
Pfizer Inc.
Novartis AG
Merck & Co., Inc.
Amgen, Inc.
Eli Lilly and Company
AbbVie Inc.
GlaxoSmithKline plc.
Bristol Myers Squibb
Sanofi Winthrop Industrie
AstraZeneca Plc.

第15章戦略的推奨事項

第16章当社について、免責事項

図表

List of Tables

Table 1. Pricing Analysis of Products from Key Players
Table 2. Competition Matrix of Top 5 Market Leaders
Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

Figure 1. Global Drug Discovery Market, By Value, In USD Billion, 2017-2031F
Figure 2. Global Drug Discovery Market, By Volume, In Million, 2017-2031F
Figure 3. Global Drug Discovery Market Share (%), By Drug Type, 2017-2031F
Figure 4. Global Drug Discovery Market Share (%), By Source, 2017-2031F
Figure 5. Global Drug Discovery Market Share (%), By Technology, 2017-2031F
Figure 6. Global Drug Discovery Market Share (%), By End-user, 2017-2031F
Figure 7. Global Drug Discovery Market Share (%), By Region, 2017-2031F
Figure 8. North America Drug Discovery Market, By Value, In USD Billion, 2017-2031F
Figure 9. North America Drug Discovery Market, By Volume, In Million, 2017-2031F
Figure 10. North America Drug Discovery Market Share (%), By Drug Type, 2017-2031F
Figure 11. North America Drug Discovery Market Share (%), By Source, 2017-2031F
Figure 12. North America Drug Discovery Market Share (%), By Technology, 2017-2031F
Figure 13. North America Drug Discovery Market Share (%), By End-user, 2017-2031F
Figure 14. North America Drug Discovery Market Share (%), By Country, 2017-2031F
Figure 15. United States Drug Discovery Market, By Value, In USD Billion, 2017-2031F
Figure 16. United States Drug Discovery Market, By Volume, In Million, 2017-2031F
Figure 17. United States Drug Discovery Market Share (%), By Drug Type, 2017-2031F
Figure 18. United States Drug Discovery Market Share (%), By Source, 2017-2031F
Figure 19. United States Drug Discovery Market Share (%), By Technology, 2017-2031F
Figure 20. United States Drug Discovery Market Share (%), By End-user, 2017-2031F
Figure 21. Canada Drug Discovery Market, By Value, In USD Billion, 2017-2031F
Figure 22. Canada Drug Discovery Market, By Volume, In Million, 2017-2031F
Figure 23. Canada Drug Discovery Market Share (%), By Drug Type, 2017-2031F
Figure 24. Canada Drug Discovery Market Share (%), By Source, 2017-2031F
Figure 25. Canada Drug Discovery Market Share (%), By Technology, 2017-2031F
Figure 26. Canada Drug Discovery Market Share (%), By End-user, 2017-2031F
Figure 27. Mexico Drug Discovery Market, By Value, In USD Billion, 2017-2031F
Figure 28. Mexico Drug Discovery Market, By Volume, In Million, 2017-2031F
Figure 29. Mexico Drug Discovery Market Share (%), By Drug Type, 2017-2031F
Figure 30. Mexico Drug Discovery Market Share (%), By Source, 2017-2031F
Figure 31. Mexico Drug Discovery Market Share (%), By Technology, 2017-2031F
Figure 32. Mexico Drug Discovery Market Share (%), By End-user, 2017-2031F
Figure 33. Europe Drug Discovery Market, By Value, In USD Billion, 2017-2031F
Figure 34. Europe Drug Discovery Market, By Volume, In Million, 2017-2031F
Figure 35. Europe Drug Discovery Market Share (%), By Drug Type, 2017-2031F
Figure 36. Europe Drug Discovery Market Share (%), By Source, 2017-2031F
Figure 37. Europe Drug Discovery Market Share (%), By Technology, 2017-2031F
Figure 38. Europe Drug Discovery Market Share (%), By End-user, 2017-2031F
Figure 39. Europe Drug Discovery Market Share (%), By Country, 2017-2031F
Figure 40. Germany Drug Discovery Market, By Value, In USD Billion, 2017-2031F
Figure 41. Germany Drug Discovery Market, By Volume, In Million, 2017-2031F
Figure 42. Germany Drug Discovery Market Share (%), By Drug Type, 2017-2031F
Figure 43. Germany Drug Discovery Market Share (%), By Source, 2017-2031F
Figure 44. Germany Drug Discovery Market Share (%), By Technology, 2017-2031F
Figure 45. Germany Drug Discovery Market Share (%), By End-user, 2017-2031F
Figure 46. France Drug Discovery Market, By Value, In USD Billion, 2017-2031F
Figure 47. France Drug Discovery Market, By Volume, In Million, 2017-2031F
Figure 48. France Drug Discovery Market Share (%), By Drug Type, 2017-2031F
Figure 49. France Drug Discovery Market Share (%), By Source, 2017-2031F
Figure 50. France Drug Discovery Market Share (%), By Technology, 2017-2031F
Figure 51. France Drug Discovery Market Share (%), By End-user, 2017-2031F
Figure 52. Italy Drug Discovery Market, By Value, In USD Billion, 2017-2031F
Figure 53. Italy Drug Discovery Market, By Volume, In Million, 2017-2031F
Figure 54. Italy Drug Discovery Market Share (%), By Drug Type, 2017-2031F
Figure 55. Italy Drug Discovery Market Share (%), By Source, 2017-2031F
Figure 56. Italy Drug Discovery Market Share (%), By Technology, 2017-2031F
Figure 57. Italy Drug Discovery Market Share (%), By End-user, 2017-2031F
Figure 58. United Kingdom Drug Discovery Market, By Value, In USD Billion, 2017-2031F
Figure 59. United Kingdom Drug Discovery Market, By Volume, In Million, 2017-2031F
Figure 60. United Kingdom Drug Discovery Market Share (%), By Drug Type, 2017-2031F
Figure 61. United Kingdom Drug Discovery Market Share (%), By Source, 2017-2031F
Figure 62. United Kingdom Drug Discovery Market Share (%), By Technology, 2017-2031F
Figure 63. United Kingdom Drug Discovery Market Share (%), By End-user, 2017-2031F
Figure 64. Russia Drug Discovery Market, By Value, In USD Billion, 2017-2031F
Figure 65. Russia Drug Discovery Market, By Volume, In Million, 2017-2031F
Figure 66. Russia Drug Discovery Market Share (%), By Drug Type, 2017-2031F
Figure 67. Russia Drug Discovery Market Share (%), By Source, 2017-2031F
Figure 68. Russia Drug Discovery Market Share (%), By Technology, 2017-2031F
Figure 69. Russia Drug Discovery Market Share (%), By End-user, 2017-2031F
Figure 70. Netherlands Drug Discovery Market, By Value, In USD Billion, 2017-2031F
Figure 71. Netherlands Drug Discovery Market, By Volume, In Million, 2017-2031F
Figure 72. Netherlands Drug Discovery Market Share (%), By Drug Type, 2017-2031F
Figure 73. Netherlands Drug Discovery Market Share (%), By Source, 2017-2031F
Figure 74. Netherlands Drug Discovery Market Share (%), By Technology, 2017-2031F
Figure 75. Netherlands Drug Discovery Market Share (%), By End-user, 2017-2031F
Figure 76. Spain Drug Discovery Market, By Value, In USD Billion, 2017-2031F
Figure 77. Spain Drug Discovery Market, By Volume, In Million, 2017-2031F
Figure 78. Spain Drug Discovery Market Share (%), By Drug Type, 2017-2031F
Figure 79. Spain Drug Discovery Market Share (%), By Source, 2017-2031F
Figure 80. Spain Drug Discovery Market Share (%), By Technology, 2017-2031F
Figure 81. Spain Drug Discovery Market Share (%), By End-user, 2017-2031F
Figure 82. Turkey Drug Discovery Market, By Value, In USD Billion, 2017-2031F
Figure 83. Turkey Drug Discovery Market, By Volume, In Million, 2017-2031F
Figure 84. Turkey Drug Discovery Market Share (%), By Drug Type, 2017-2031F
Figure 85. Turkey Drug Discovery Market Share (%), By Source, 2017-2031F
Figure 86. Turkey Drug Discovery Market Share (%), By Technology, 2017-2031F
Figure 87. Turkey Drug Discovery Market Share (%), By End-user, 2017-2031F
Figure 88. Poland Drug Discovery Market, By Value, In USD Billion, 2017-2031F
Figure 89. Poland Drug Discovery Market, By Volume, In Million, 2017-2031F
Figure 90. Poland Drug Discovery Market Share (%), By Drug Type, 2017-2031F
Figure 91. Poland Drug Discovery Market Share (%), By Source, 2017-2031F
Figure 92. Poland Drug Discovery Market Share (%), By Technology, 2017-2031F
Figure 93. Poland Drug Discovery Market Share (%), By End-user, 2017-2031F
Figure 94. South America Drug Discovery Market, By Value, In USD Billion, 2017-2031F
Figure 95. South America Drug Discovery Market, By Volume, In Million, 2017-2031F
Figure 96. South America Drug Discovery Market Share (%), By Drug Type, 2017-2031F
Figure 97. South America Drug Discovery Market Share (%), By Source, 2017-2031F
Figure 98. South America Drug Discovery Market Share (%), By Technology, 2017-2031F
Figure 99. South America Drug Discovery Market Share (%), By End-user, 2017-2031F
Figure 100. South America Drug Discovery Market Share (%), By Country, 2017-2031F
Figure 101. Brazil Drug Discovery Market, By Value, In USD Billion, 2017-2031F
Figure 102. Brazil Drug Discovery Market, By Volume, In Million, 2017-2031F
Figure 103. Brazil Drug Discovery Market Share (%), By Drug Type, 2017-2031F
Figure 104. Brazil Drug Discovery Market Share (%), By Source, 2017-2031F
Figure 105. Brazil Drug Discovery Market Share (%), By Technology, 2017-2031F
Figure 106. Brazil Drug Discovery Market Share (%), By End-user, 2017-2031F
Figure 107. Argentina Drug Discovery Market, By Value, In USD Billion, 2017-2031F
Figure 108. Argentina Drug Discovery Market, By Volume, In Million, 2017-2031F
Figure 109. Argentina Drug Discovery Market Share (%), By Drug Type, 2017-2031F
Figure 110. Argentina Drug Discovery Market Share (%), By Source, 2017-2031F
Figure 111. Argentina Drug Discovery Market Share (%), By Technology, 2017-2031F
Figure 112. Argentina Drug Discovery Market Share (%), By End-user, 2017-2031F
Figure 113. Asia-Pacific Drug Discovery Market, By Value, In USD Billion, 2017-2031F
Figure 114. Asia-Pacific Drug Discovery Market, By Volume, In Million, 2017-2031F
Figure 115. Asia-Pacific Drug Discovery Market Share (%), By Drug Type, 2017-2031F
Figure 116. Asia-Pacific Drug Discovery Market Share (%), By Source, 2017-2031F
Figure 117. Asia-Pacific Drug Discovery Market Share (%), By Technology, 2017-2031F
Figure 118. Asia-Pacific Drug Discovery Market Share (%), By End-user, 2017-2031F
Figure 119. Asia-Pacific Drug Discovery Market Share (%), By Country, 2017-2031F
Figure 120. India Drug Discovery Market, By Value, In USD Billion, 2017-2031F
Figure 121. India Drug Discovery Market, By Volume, In Million, 2017-2031F
Figure 122. India Drug Discovery Market Share (%), By Drug Type, 2017-2031F
Figure 123. India Drug Discovery Market Share (%), By Source, 2017-2031F
Figure 124. India Drug Discovery Market Share (%), By Technology, 2017-2031F
Figure 125. India Drug Discovery Market Share (%), By End-user, 2017-2031F
Figure 126. China Drug Discovery Market, By Value, In USD Billion, 2017-2031F
Figure 127. China Drug Discovery Market, By Volume, In Million, 2017-2031F
Figure 128. China Drug Discovery Market Share (%), By Drug Type, 2017-2031F
Figure 129. China Drug Discovery Market Share (%), By Source, 2017-2031F
Figure 130. China Drug Discovery Market Share (%), By Technology, 2017-2031F
Figure 131. China Drug Discovery Market Share (%), By End-user, 2017-2031F
Figure 132. Japan Drug Discovery Market, By Value, In USD Billion, 2017-2031F
Figure 133. Japan Drug Discovery Market, By Volume, In Million, 2017-2031F
Figure 134. Japan Drug Discovery Market Share (%), By Drug Type, 2017-2031F
Figure 135. Japan Drug Discovery Market Share (%), By Source, 2017-2031F
Figure 136. Japan Drug Discovery Market Share (%), By Technology, 2017-2031F
Figure 137. Japan Drug Discovery Market Share (%), By End-user, 2017-2031F
Figure 138. Australia Drug Discovery Market, By Value, In USD Billion, 2017-2031F
Figure 139. Australia Drug Discovery Market, By Volume, In Million, 2017-2031F
Figure 140. Australia Drug Discovery Market Share (%), By Drug Type, 2017-2031F
Figure 141. Australia Drug Discovery Market Share (%), By Source, 2017-2031F
Figure 142. Australia Drug Discovery Market Share (%), By Technology, 2017-2031F
Figure 143. Australia Drug Discovery Market Share (%), By End-user, 2017-2031F
Figure 144. Vietnam Drug Discovery Market, By Value, In USD Billion, 2017-2031F
Figure 145. Vietnam Drug Discovery Market, By Volume, In Million, 2017-2031F
Figure 146. Vietnam Drug Discovery Market Share (%), By Drug Type, 2017-2031F
Figure 147. Vietnam Drug Discovery Market Share (%), By Source, 2017-2031F
Figure 148. Vietnam Drug Discovery Market Share (%), By Technology, 2017-2031F
Figure 149. Vietnam Drug Discovery Market Share (%), By End-user, 2017-2031F
Figure 150. South Korea Drug Discovery Market, By Value, In USD Billion, 2017-2031F
Figure 151. South Korea Drug Discovery Market, By Volume, In Million, 2017-2031F
Figure 152. South Korea Drug Discovery Market Share (%), By Drug Type, 2017-2031F
Figure 153. South Korea Drug Discovery Market Share (%), By Source, 2017-2031F
Figure 154. South Korea Drug Discovery Market Share (%), By Technology, 2017-2031F
Figure 155. South Korea Drug Discovery Market Share (%), By End-user, 2017-2031F
Figure 156. Indonesia Drug Discovery Market, By Value, In USD Billion, 2017-2031F
Figure 157. Indonesia Drug Discovery Market, By Volume, In Million, 2017-2031F
Figure 158. Indonesia Drug Discovery Market Share (%), By Drug Type, 2017-2031F
Figure 159. Indonesia Drug Discovery Market Share (%), By Source, 2017-2031F
Figure 160. Indonesia Drug Discovery Market Share (%), By Technology, 2017-2031F
Figure 161. Indonesia Drug Discovery Market Share (%), By End-user, 2017-2031F
Figure 162. Philippines Drug Discovery Market, By Value, In USD Billion, 2017-2031F
Figure 163. Philippines Drug Discovery Market, By Volume, In Million, 2017-2031F
Figure 164. Philippines Drug Discovery Market Share (%), By Drug Type, 2017-2031F
Figure 165. Philippines Drug Discovery Market Share (%), By Source, 2017-2031F
Figure 166. Philippines Drug Discovery Market Share (%), By Technology, 2017-2031F
Figure 167. Philippines Drug Discovery Market Share (%), By End-user, 2017-2031F
Figure 168. Middle East & Africa Drug Discovery Market, By Value, In USD Billion, 2017-2031F
Figure 169. Middle East & Africa Drug Discovery Market, By Volume, In Million, 2017-2031F
Figure 170. Middle East & Africa Drug Discovery Market Share (%), By Drug Type, 2017-2031F
Figure 171. Middle East & Africa Drug Discovery Market Share (%), By Source, 2017-2031F
Figure 172. Middle East & Africa Drug Discovery Market Share (%), By Technology, 2017-2031F
Figure 173. Middle East & Africa Drug Discovery Market Share (%), By End-user, 2017-2031F
Figure 174. Middle East & Africa Drug Discovery Market Share (%), By Country, 2017-2031F
Figure 175. Saudi Arabia Drug Discovery Market, By Value, In USD Billion, 2017-2031F
Figure 176. Saudi Arabia Drug Discovery Market, By Volume, In Million, 2017-2031F
Figure 177. Saudi Arabia Drug Discovery Market Share (%), By Drug Type, 2017-2031F
Figure 178. Saudi Arabia Drug Discovery Market Share (%), By Source, 2017-2031F
Figure 179. Saudi Arabia Drug Discovery Market Share (%), By Technology, 2017-2031F
Figure 180. Saudi Arabia Drug Discovery Market Share (%), By End-user, 2017-2031F
Figure 181. UAE Drug Discovery Market, By Value, In USD Billion, 2017-2031F
Figure 182. UAE Drug Discovery Market, By Volume, In Million, 2017-2031F
Figure 183. UAE Drug Discovery Market Share (%), By Drug Type, 2017-2031F
Figure 184. UAE Drug Discovery Market Share (%), By Source, 2017-2031F
Figure 185. UAE Drug Discovery Market Share (%), By Technology, 2017-2031F
Figure 186. UAE Drug Discovery Market Share (%), By End-user, 2017-2031F
Figure 187. South Africa Drug Discovery Market, By Value, In USD Billion, 2017-2031F
Figure 188. South Africa Drug Discovery Market, By Volume, In Million, 2017-2031F
Figure 189. South Africa Drug Discovery Market Share (%), By Drug Type, 2017-2031F
Figure 190. South Africa Drug Discovery Market Share (%), By Source, 2017-2031F
Figure 191. South Africa Drug Discovery Market Share (%), By Technology, 2017-2031F
Figure 192. South Africa Drug Discovery Market Share (%), By End-user, 2017-2031F
Figure 193. By Drug Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 194. By Source Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 195. By Technology Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 196. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 197. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023

Product Code: MX10829

Global drug discovery market size was valued at USD 68.24 billion in 2023, which is expected to reach USD 154.12 billion in 2031, with a CAGR of 10.72% for the forecast period between 2024 and 2031F. Growth in global drug discovery market is driven by various factors such as rising prevalence of various chronic diseases, increasing healthcare expenditure, patent expiration of certain popular drugs, adoption of AI solutions, and increasing investments in private and public sector in the biomedical research.

The global drug discovery market is further undergoing robust growth due to an increase in the elderly population. Decrease in fertility rates, increase in life expectancy due to an increase in healthcare facilities, and vast treatment options available worldwide for the elderly population are the factors helping people to live longer. However, it has further accelerated age-related modalities and chronic diseases among the population. To combat these modalities, innovation and research & development in drug discovery are needed. Moreover, each country has its own set of regulations that are responsible to check the safety and efficacy of the approved drug to ensure and maintain the quality and standard of the drug at every step to improve the health of the population.

The COVID-19 pandemic has accelerated the movement of care resulting in increased healthcare expenditure across different countries. The increased healthcare expenditure has surged in global drug discovery market due to increased spending on research, drug development, and manufacturing process. Drug discovery is an expensive, complex, and sensitive process that requires funding from the government and pharmaceutical industry, due to the costs and risks associated with pharmaceutical R&D. Healthcare spending results in better provision of health opportunities that further strengthens the healthcare system of a country and simultaneously leads to the growth of global drug discovery market.

Increasing Prevalence of Chronic Diseases

The increasing prevalence of chronic diseases is a major driving factor for the global drug discovery market. According to WHO, chronic diseases including cardiovascular diseases, cancer, diabetes, and respiratory illnesses are responsible for 41 million deaths every year at global level. It affects people of all age groups, irrespective of their region and countries. Unhealthy diet, sedentary lifestyle, tobacco use, and alcohol abuse are the leading risk factors for the rising chronic diseases in developing as well as developed countries. The increasing prevalence is further propelling the demand for new drug discoveries. To achieve the goal of a healthier future, pharmaceutical companies are accelerating research and development for discovering new medicines. Drug discoveries are required to treat symptoms of new diseases, chronic diseases, untreatable diseases, and to solve the issue of drug resistance. As life expectancy is increasing, people are more prone to getting exposed to these diseases, resulting in growth of global drug discovery market.

Increased Investments in Drug discovery

Significant public and private investments are needed to support the manufacturing of drugs, whether they are small molecule drugs, protein-based biologic drugs, vaccines, or in vivo diagnostics. These investments by the organizations is thriving the global drug discovery market to meet the global healthcare goals. With increase in chronic diseases and new diseases encounters, the need for developing and discovering new drugs to tackle the health issues of the growing population is the need of the hour. To meet this demand, many biotech companies in USA, Europe, and APAC have raised big investments in drug discoveries.

For instance, in September 2023, Generate Biomedicines raised USD 273 million in a Series C round to advance its generative AI pipeline of preclinical and clinical protein therapeutics. In the same month September 2023, Grit Biotechnology raised USD 60 million in a Series B round. Grit Biotechnology has its specialization in the field of tumor immunotherapy, and this investment will further support its tumor-infiltrating lymphocyte (TIL) pipeline development in the future. Hence, these investments in the drug developing process are expected to accelerate the global drug discovery market.

Government Initiatives

Drug discovery is a time consuming and expensive process and requires funds and support from the government on its various manufacturing steps. The Government has devoted billions for drug discovery R&D. The expenditure has covered a variety of activities such as discovering and testing new drugs, developing innovations, and clinical testing for safety-monitoring purpose. Government has launched many initiatives, policies, and programs to help and support global drug discovery market. For instance, according to an article published by US Government Accountability Office (GAO) on September 2023, The National Institutes of Health (NIH) has identified many viral families that have the potential to cause future pandemics. To combat these viral diseases there is a need to develop antiviral drugs. GAO has identified some technologies like artificial intelligence to speed up antiviral drug development process. In 2022, the White House issued the National Biodefense Strategy and Implementation Plan to support this agenda of antiviral drugs development.

Growing Demand for Biologics

There has been a notable surge in demand for biologics in the global drug discovery market. The category of Biologics is gaining momentum due to its huge potential to treat diseases, which are considered untreatable or difficult to treat. Biologics have attributes that makes them more specific to treat the targeted disease and are less likely to react with other drugs. Hence, they ensure safety of the patients who are taking multiple drugs. These attributes have resulted in an upsurge in demand for biologics and many countries, including Japan, the United Kingdom, India, China, the United States, and Sweden, beginning to develop complex biomanufacturing facilities to meet this rising demand. Major pharmaceutical corporations are entering the biologics space, for instance, in September 2023, Takeda Pharmaceuticals, Inc. got approval from Center for Biologics Evaluation and Research (CBER) for biologics named ADZYNMA, which is indicated for prophylactic or on demand enzyme replacement therapy (ERT) in adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP).

Use of AI in Drug Discovery

Drug development is a long, complex, and uncertain process that takes an average of 10-12 years to develop. The pharmaceutical industry is trying to create a fast and effective solution for drug development, and hence, companies are applying various computational methods to reach that goal. A novel technology called computer-aided drug design, or CADD, is used in the drug discovery process to find and develop a possible lead. Molecular modelling, molecular design, rational drug design and computational chemistry are all part of CADD. The use of AI can simplify and facilitate drug design by filtering datasets available. With the use of healthcare related data available in the records along with latest innovation in AI and Machine learning, it is possible to analyze the data and use it for faster and accurate outcomes. Thus, we can say that use of AI in drug discovery is further accelerating the global drug discovery market.

Many companies are using AI in their drug development process, for instance, on November 21, 2023, Genentech, a member of the Roche Group announced a multi-year strategic research collaboration with NVIDIA to use artificial intelligence (AI) to speed up drug discovery and development. NVIDIA and Genentech collaboration will help Genentech's AI/ML teams, to leverage AI and ML foundational models across numerous research areas including diverse therapeutic modalities as well as will help in gaining new insights, promoting growth in the global drug discovery market.

Future Market Scenario

Global drug discovery market is expected to grow in the coming years, due to multiple factors. Primarily, the increasing global aging population has led to a higher incidence of chronic illnesses such as cardiovascular diseases, cancer, diabetes, respiratory illness, and many more. Additionally, growth in the development of biosimilars and increased use of AI by the drugs manufacturing companies is further propelling the growth in the global drug discovery market. Other important driving factors are governmental support, policies, increase in healthcare expenditure and pharmaceutical regulatory agencies and organizations. The regulatory bodies maintain the safety and efficacy of the newly approved drug by thoroughly examining the drug manufacturing process. Collaborative ventures involving pharmaceutical companies, research institutions, and biotechnology firms have spurred innovation.

Key Players Landscape and Outlook

In the drug discovery market, companies progressively establish strategic partnerships and distribution agreements, which plays a pivotal role in market expansion. These alliances empower firms to harness each other's strengths, gain access to new markets and technologies, and pool resources for research and development endeavors. Distribution agreements enable companies to broaden their market presence at an international level. These collaborative initiatives promote innovation, expedite product development, and contribute to robust growth in the drug discovery market. In September 2023, Ono Pharmaceutical Co., Ltd., a Japanese firm announced that it has entered into a drug discovery collaboration agreement with Adimab, LLC., which is a global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies. The collaboration aims to discover and develop innovative antibody drugs in the oncology field.

1. Research Methodology

2. Project Scope & Definitions

3. Future Outlook of Global Drug Discovery Market

4. Executive Summary

5. Global Drug Discovery Market Outlook, 2017-2031F

5.1. Market Size & Forecast
- 5.1.1. Value
- 5.1.2. Volume
5.2. By Drug Type
- 5.2.1. Small Molecules
- 5.2.2. Biologics
5.3. By Source
- 5.3.1. Natural
- 5.3.2. Synthetic
5.4. By Technology
- 5.4.1. Combinatorial chemistry
- 5.4.2. High-throughput screening
- 5.4.3. Nanotechnology
- 5.4.4. Pharmacogenomics
- 5.4.5. Other Technologies
5.5. By End-user
- 5.5.1. Pharmaceutical Companies
- 5.5.2. Contract Research Organizations
- 5.5.3. Others
5.6. By Region
- 5.6.1. North America
- 5.6.2. Europe
- 5.6.3. South America
- 5.6.4. Asia-Pacific
- 5.6.5. Middle East and Africa
5.7. By Company Market Share (%), 2023

6. Global Drug Discovery Market Outlook, By Region, 2017-2031F

6.1. North America*
- 6.1.1. Market Size & Forecast
  - 6.1.1.1. Value
  - 6.1.1.2. Volume
- 6.1.2. By Drug Type
  - 6.1.2.1. Small Molecules
  - 6.1.2.2. Biologics
- 6.1.3. By Source
  - 6.1.3.1. Natural
  - 6.1.3.2. Synthetic
- 6.1.4. By Technology
  - 6.1.4.1. Combinatorial chemistry
  - 6.1.4.2. High-throughput screening
  - 6.1.4.3. Nanotechnology
  - 6.1.4.4. Pharmacogenomics
  - 6.1.4.5. Other Technologies
- 6.1.5. By End-user
  - 6.1.5.1. Pharmaceutical Companies
  - 6.1.5.2. Contract Research Organizations
  - 6.1.5.3. Others
- 6.1.6. United States*
  - 6.1.6.1. Market Size & Forecast
  - 6.1.6.1.1. Value
  - 6.1.6.1.2. Volume
  - 6.1.6.2. By Drug Type
  - 6.1.6.2.1. Small Molecules
  - 6.1.6.2.2. Biologics
  - 6.1.6.3. By Source
  - 6.1.6.3.1. Natural
  - 6.1.6.3.2. Synthetic
  - 6.1.6.4. By Technology
  - 6.1.6.4.1. Combinatorial chemistry
  - 6.1.6.4.2. High-throughput screening
  - 6.1.6.4.3. Nanotechnology
  - 6.1.6.4.4. Pharmacogenomics
  - 6.1.6.4.5. Other Technologies
  - 6.1.6.5. By End-user
  - 6.1.6.5.1. Pharmaceutical Companies
  - 6.1.6.5.2. Contract Research Organizations
  - 6.1.6.5.3. Others
- 6.1.7. Canada
- 6.1.8. Mexico

All segments will be provided for all regions and countries covered:

6.2. Europe
- 6.2.1 Germany
- 6.2.2 France
- 6.2.3 Italy
- 6.2.4 United Kingdom
- 6.2.5 Russia
- 6.2.6 Netherlands
- 6.2.7 Spain
- 6.2.8 Turkey
- 6.2.9 Poland
6.3. South America
- 6.3.1. Brazil
- 6.3.2. Argentina
6.4. Asia Pacific
- 6.4.1. India
- 6.4.2. China
- 6.4.3. Japan
- 6.4.4. Australia
- 6.4.5. Vietnam
- 6.4.6. South Korea
- 6.4.7. Indonesia
- 6.4.8. Philippines
6.5. Middle East & Africa
- 6.5.1. Saudi Arabia
- 6.5.2. UAE
- 6.5.3. South Africa

7. Market Mapping, 2023

7.1. By Drug Type
7.2. By Source
7.3. By Technology
7.4. By End-user
7.5. By Region

8. Macro Environment and Industry Structure

8.1. Supply Demand Analysis
8.2. Import Export Analysis
8.3. Value Chain Analysis
8.4. PESTEL Analysis
- 8.4.1. Political Factors
- 8.4.2. Economic System
- 8.4.3. Social Implications
- 8.4.4. Technological Advancements
- 8.4.5. Environmental Impacts
- 8.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
8.5. Porter's Five Forces Analysis
- 8.5.1. Supplier Power
- 8.5.2. Buyer Power
- 8.5.3. Substitution Threat
- 8.5.4. Threat from New Entrant
- 8.5.5. Competitive Rivalry

9. Market Dynamics

9.1. Growth Drivers
9.2. Growth Inhibitors (Challenges and Restraints)

10. Regulatory Framework and Innovation

10.1 Clinical Trials
10.2 Patent Landscape
10.3 Regulatory Approvals
10.4 Innovations/Emerging Technologies

11. Key Players Landscape

11.1. Competition Matrix of Top Five Market Leaders
11.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
11.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
11.4. SWOT Analysis (For Five Market Players)
11.5. Patent Analysis (If Applicable)

12. Pricing Analysis

13. Case Studies

14. Key Players Outlook

14.1. Johnson & Johnson Inc.
- 14.1.1. Company Details
- 14.1.2. Key Management Personnel
- 14.1.3. Products & Services
- 14.1.4. Financials (As reported)
- 14.1.5. Key Market Focus & Geographical Presence
- 14.1.6. Recent Developments
14.2. F. Hoffmann-La Roche Ltd.
14.3. Pfizer Inc.
14.4. Novartis AG
14.5. Merck & Co., Inc.
14.6. Amgen, Inc.
14.7. Eli Lilly and Company
14.8. AbbVie Inc.
14.9. GlaxoSmithKline plc.
14.10. Bristol Myers Squibb
14.11. Sanofi Winthrop Industrie
14.12. AstraZeneca Plc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

創薬の世界市場の評価：医薬品タイプ別、由来別、技術別、エンドユーザー別、地域別、機会、予測（2017年～2031年）

Global Drug Discovery Market Assessment, By Drug Type, By Source, By Technology, By End-user, By Region, Opportunities and Forecast, 2017-2031F

慢性疾患の流行

創薬への投資の増加

政府の取り組み

高まる生物学的製剤の需要

目次

第1章 調査手法

第2章 プロジェクトの範囲と定義

第3章 世界の創薬市場の将来の見通し

第4章 エグゼクティブサマリー

第5章 世界の創薬市場の見通し（2017年～2031年）

第6章 世界の創薬市場の見通し：地域別（2017年～2031年）

第7章 市場マッピング（2023年）

第8章 マクロ環境と産業構造

第9章 市場力学

第10章 規制枠組みとイノベーション

第11章 主要企業情勢

第12章 価格分析

第13章 ケーススタディ

第14章 主要企業の見通し

第15章 戦略的推奨事項

第16章 当社について、免責事項